€304.4 mln

Product sales in 2009
Compared to €226.1 mln in 2008.

€327.8 mln

Cash and cash equivalents at year-end 2009
Strong cash position to invest in profitable growth.

€0.34

Net profit per share in 2009
Compared to net profit shareof €0.22 in 2008.

Crucell at a glance

Crucell is a fully integrated biopharmaceutical company. We focus on developing, producing and marketing products that combat infectious diseases.

Who we are

Crucell is a fully integrated biopharmaceutical company dedicated to bringing meaningful innovation to global health by developing, producing and marketing products to combat infectious diseases. Innovation is the driving force behind our strong research & development (R&D) pipeline, with promising products in pre-clinical and clinical development. Crucell product candidates include flu-mAb, an antibody product effective against a broad range of influenza virus strains, tuberculosis and malaria vaccines, as well as a rabies monoclonal antibody combination–all produced on our unique PER.C6® human cell-line technology. The sustainability of our business is demonstrated by our solid balance sheet and our strong cash flow. For a company of our size, we invest heavily in R&D: our R&D expenditures in 2009 were €70.2 million.

Strategy

We develop products that address currently unmet medical needs, particularly in the field of infectious diseases. We have a fully integrated infrastructure for in-house development, production and marketing of vaccines, and we are leveraging our knowledge in the vaccines field to excel in the antibodies market. Our competitive edge comes from our proprietary technology platforms like PER.C6®, which is ideally suited for the manufacture of vaccines and therapeutic proteins, such as antibodies. Compared to traditional production platforms, PER.C6® technology offers much higher yields at lower cost, as well as safety advantages. The markets we operate in, our technological knowledge and our quality marketed products position us to be a major player in the multi-billion dollar biopharmaceutical arena.

We focus on the paediatric, travel & endemic and respiratory markets. Our core product portfolio includes Quinvaxem®, a fully liquid pentavalent vaccine against five important childhood diseases; Epaxal®, the only aluminum-free hepatitis A vaccine on the market; Vivotif® and Dukoral®, oral vaccines against typhoid and cholera; and Inflexal® V, a virosomal adjuvanted vaccine against influenza. In 2009 we distributed more than 115 million doses of vaccines in over 100 countries, focusing strongly– but not exclusively–on unmet medical needs in developing countries.

Partners and licensees

In addition to our own R&D activities, we have strategic partnerships with several leading healthcare companies. Through these agreements, our technologies play a vital role in the development of a vast number of vaccines and antibody products. Some of our partners and licensees are listed below.

  • Cangene
  • Centocor
  • CSL
  • DSM Biologics
  • Gedeon Richter
  • GSK
  • Johnson & Johnson
  • MedImmune
  • Merck
  • Novartis
  • sanofi pasteur
  • Talecris
  • TapImmune
  • Wyeth

Why infectious diseases?

Infectious diseases currently account for a significant number of human casualties throughout the world. The number of infectious outbreaks is increasing for many reasons: higher population density which raises exposure to infectious agents; an ageing population which is more susceptible to infection; and a rise in global travel which boosts the potential for spreading diseases across borders.

Back to top